Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Catheter Cardiovasc Interv. 2010 Jul 1;76(1):145-50. doi: 10.1002/ccd.22475.
Moderate-to-large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA).
All patients undergoing percutaneous PFO closure were routinely screened at six-months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate-to-large residual shunts were selected to undergo reintervention with shunt closure. Post-reintervention follow-up was performed at 24-hr, 30 days, and every six months thereafter. Clinical predictors of the moderate-to-large residual shunts, and the feasibility, safety and long-term efficacy of percutaneous residual shunt closure using a second device implant were examined.
Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate-to-large residual shunts. Baseline characteristics among patients with moderate-to-large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24-hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate-to-large residual shunt (mean age, 47 +/- 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long-term mean follow-up period of 2.9 years.
Our study suggests that in patients with moderate-to-large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective.
经皮卵圆孔未闭(PFO)封堵术后中等至大残余分流是临床重要的,并与复发性神经栓塞事件相关。然而,其管理在临床实践中尚未明确确立。我们报告了我们在既往有隐源性中风和/或短暂性脑缺血发作(TIA)病史的这些患者中的经验。
所有接受经皮 PFO 封堵术的患者均在术后 6 个月常规使用经胸 2D 超声心动图,在前臂应用搅拌盐水对比剂和彩色血流多普勒筛查残余分流。选择有中等至大残余分流证据的患者进行分流关闭的再介入治疗。再介入治疗后 24 小时、30 天和此后每 6 个月进行随访。检查中等至大残余分流的临床预测因素,以及使用第二种装置植入物进行经皮残余分流关闭的可行性、安全性和长期疗效。
1995 年至 2007 年间,共有 424 例患者接受了 PFO 封堵术。其中,5%(21/424)有中等至大残余分流。在有中等至大残余分流的患者和仅有无或小缺陷的患者(n=403)之间,基线特征相似。多变量分析确定 24 小时术后分流是 6 个月时残余分流的唯一独立预测因素。在 21 例有中等至大残余分流的研究患者(平均年龄 47±14)中,1 例成功接受了选择性手术修复,而其余 20 例接受了使用第二种装置的经导管关闭。该技术成功率为 95%(19/20),所有患者除 1 例外,在经皮再介入治疗后的 6 个月均完全关闭分流。在长达 2.9 年的平均随访期间,我们没有报告死亡、复发性中风或 TIA。
我们的研究表明,对于中等至大残余 PFO 分流患者,使用第二种装置植入物进行经皮再介入治疗是安全有效的。